title: PCV salvage chemotherapy for recurrent primary CNS lymphoma.
authors.affiliation: Departments of Neurology, University of Tübingen, Tübingen, Germany. ulrich.herrlinger@uni-tuebingen.de
authors.forename: U
authors.initials: U
authors.lastname: Herrlinger
authors.forename: W
authors.initials: W
authors.lastname: Brugger
authors.forename: M
authors.initials: M
authors.lastname: Bamberg
authors.forename: W
authors.initials: W
authors.lastname: Küker
authors.forename: J
authors.initials: J
authors.lastname: Dichgans
authors.forename: M
authors.initials: M
authors.lastname: Weller
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D008130:Lomustine / Q000009:adverse effects / Q000627:therapeutic use; D008223:Lymphoma / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011344:Procarbazine / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D016879:Salvage Therapy; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine